Select Biotechnology Portfolio
Actively managed U.S. stock fund
As of its 2026 Q2 report, Select Biotechnology Portfolio held 215 positions with $5.27B in net assets. Its ten largest holdings made up 46.4% of the fund. The FBIOX share class costs 0.62% a year. Over the 12 months to May 2026, FBIOX returned 55.7%, with dividends reinvested. In 2026 Q2 it added 36 new positions and exited 12.
Biotechnology Portfolio seeks capital appreciation.
The fund invests at least 80% of assets in common stocks of companies principally engaged in biotechnology research, development, manufacturing, and distribution, including those focused on genetic analysis and genetic engineering, selected through fundamental analysis of financial condition, industry position, and market conditions. The fund may invest in both domestic and foreign issuers. Because the fund's classification of companies as principally engaged in biotechnology relies on asset, income, sales, or profit metrics or third-party industry classifications, the fund's holdings may diverge from what different analysts would consider core biotechnology exposure.
What you own
| Company | Weight | Value | Shares | Reported price |
|---|---|---|---|---|
10.58% | $557.06M | 1.8M | $309.03 | |
ABBVABBVIE INC | 9.22% | $485.56M | 2.2M | $217.72 |
AMGNAMGEN INC | 6.53% | $343.86M | 1.0M | $336.79 |
4.82% | $253.58M | 1.9M | $134.43 | |
Fidelity Revere Street Trust | 3.35% | $176.49M | — | — |
2.93% | $154.52M | 511.7K | $301.98 | |
2.47% | $129.99M | 371.4K | $349.97 | |
INSMINSMED INC | 2.25% | $118.58M | 1.1M | $106.91 |
ARGXARGENX SE | 2.25% | $118.25M | 141.4K | $835.99 |
ASCENDIS PHARMA A/S | 2.04% | $107.66M | 480.4K | $224.11 |
Reported price is the fund's own reported value divided by its own reported shares at 2026-05-31 — not a live quote, and not what the fund paid.
The 200 largest of 215 holdings, with the share counts as filed, open with a free account.
What the fund is made of
Percentages are of fund net assets. Rounding, liabilities and short positions can make totals differ from 100%.
| Stocks | 99.89% |
| Cash & short-term | 3.51% |
By sector
- Health Care
- 83.0%
- International
- 11.7%
- Cash
- 3.4%
- Other
- 1.7%
- 1 other sector
- 0.2%
- Health Care
- 83.0%
- International
- 11.7%
- Cash
- 3.4%
- Other
- 1.7%
- Industrials
- 0.2%
How it has done
FBIOX share class · total returns with dividends reinvested
Volatility over the last 12 months: 12.55%. Past returns are a record, not a forecast.
Fees & fund details
Select Biotechnology Portfolio is an actively managed U.S. equity fund.
- Asset class
- Equity
- Region
- United States
- Management
- Actively managed
- Fund type
- Open-end fund
- Features
- Non-diversified
- Expense ratio, by class
- 0.62%· FBIOX 0.62%
- Portfolio turnover
- 45.00% a year · as of 2026 Q2
Turnover is how much of the portfolio was replaced in a year.
Classified from what the fund holds, not from its name · 2026 Q2. The summary is a paraphrase of the prospectus; the objective is verbatim.
What changed this quarter
Positions that entered or left the fund since its previous filing. Positions that were only resized are not listed.
36 new· the largest 8
12 exited· the largest 8
Understand how this fund fits with the rest.
Explore shared holdings, compare funds and follow their businesses with your connected AI:
- “Where do my funds overlap — FBIOX, QQQ and the fund in my 401(k)?”
- “How do this fund’s ten biggest holdings stack up against each other?”
- “For my target-date fund, what’s the real stock-and-bond mix once you look through it?”